Articles related to MYELOMA

AL amyloidosis, a rare disease with an estimated global incidence of 10 cases per million population, can present with various symptoms depending on organ involvement, making early diagnosis challenging but crucial for effective treatment.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

High-risk iFISH markers, such as CKS1B, IGH-FGFR3, and del17p, significantly affect survival outcomes in newly diagnosed multiple myeloma patients, with marked differences observed between high-risk and standard-risk cohorts.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.